

8. Literatur

1. Albino JA, Reichman LB: The treatment of tuberculosis. *Respiration* 1998; 65:237-255
2. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R, Raviglione MC: European framework for tuberculosis control and elimination in countries with a low incidence. *Eur Respir J* 2002; 19:765-775
3. Chaves F, Dronda F, Cave MD, Alonso-Sanz M, Gonzalez-Lopez A, Eisenach KD, Ortega A, Lopez-Cubero L, Fernandez-Martin I, Catalan S, Bates JH: A longitudinal study of transmission of tuberculosis in a large prison population. *Am J Resp Crit Care Med* 1997; 155:719-725
4. Clancy L, Rieder HL, Enarson DA, Spinaci S: Tuberculosis elimination in the countries of Europe and other industrialised countries. *Eur Respir J* 1991; 4: 1288-1295
5. Clancy L: Control of tuberculosis in low-prevalence countries. In Davies PDO (Hrsg): *Clinical Tuberculosis 2nd Ed* 1998; Chapman & Hall, London: 435-450
6. Cole S, Telenti A: Drug resistance in *Mycobacterium tuberculosis*. *Eur Respir J* 1995; 8:Suppl. 20,701s-713s
7. Coninx R, Maher D, Reyes H, Grzemska M: Tuberculosis in prisons in countries with high prevalence. *BMJ* 2000; 320:440-442
8. Crofton J, Chaulet P, Maher D: Guidelines for the management of drug-resistant tuberculosis. WHO 1996 Geneva. WHO/TB96.210 (Rev.1)
9. Davies PDO: Tuberculosis and migration. The Mitchell Lecture 1994. *J R Coll Physicians London* 1995; 29(2):113-118
10. Davies PDO: A European framework for effective tuberculosis control (Editorial). *Eur Respir J* 2002; 19:590-592
11. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose: 27. Informationsbericht. pmi Verlagsgruppe Frankfurt/Main 2002
12. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose: 28. Informationsbericht. DZK, Berlin 2004
13. Drobniewski FA, Uttley AC: Tuberculosis treatment programmes. *Lancet* 1994; 344:610
14. Drobniewski F: Tuberculosis in prisons - forgotten plague. *Lancet* 1995; 346:948-49
15. Drobniewski F, Taylor E, Ignatenko N, Paul J, Connolly M, Nye P, Lyagoshina T, Besse C: Tuberculosis in Siberia 1. An epidemiological and microbiological assessment. *Tubercle and Lung Disease* 1996; 77:199-206
16. Drobniewski F, Taylor E, Ignatenko N, Paul J, Connolly M, Nye P, Lyagoshina T, Besse C: Tuberculosis in Siberia 2. Diagnosis, chemoprophylaxis and treatment. *Tubercle and Lung Disease* 1996; 77:297-301

17. Espinal MA, Dye C, Raviglione M, Kochi A: Rational DOTS-Plus for the control of MDR-TB. *Int J Tuberc Lung Dis* 1999; 3:561-563
18. Espinal M, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC: Global trends in resistance to antituberculosis drugs. *N Engl J Med* 2001; 344:1294-1303
19. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, Smith I, Suarez P, Antunes ML, George AG, Martin-Casabona N, Simelane P, Weyer K, Binkin N, Raviglione MC: Determinants of drug-resistant tuberculosis: analysis of 11 countries. *Int J Tuberc Lung Dis* 2001; 5:887-893
20. EuroTB: Surveillance of Tuberculosis in Europe. Report on tuberculosis cases notified in 1999. Maulde & Renou, Paris 2002
21. EuroTB: Surveillance of Tuberculosis in Europe. Report on tuberculosis cases notified in 2000. Maulde & Renou, Paris 2003
22. Fanning A: The importance of education, training and supervision in global TB control. *Int J Tuberc Lung Dis* 2000; 4:S208-214
23. Farmer P: Managerial successes, clinical failures (Editorial). *Int J Tuberc Lung Dis* 1999; 3:365-367
24. Farmer PA, Kononets AS, Borisov SE, Goldfarb A, Healing T, McKee M: Re-crudescent tuberculosis in Russian Federation. The global impact of drug-resistant tuberculosis. Boston: Harvard Medical School Open Society Institute, Department of Social Medicine 1999; 39-84
25. Fine PE: Variation in protection by BCG: Implications of and for heterologous immunity. *Lancet* 1995; 436:1339-1345
26. Forßbohm M: Studie des DZK zur Epidemiologie der Tuberkulose. Abschlussbericht 1996-2000. In: Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose: 28. Informationsbericht. DZK 2004; 66-78
27. Frieden TR: Can tuberculosis be controlled? *International Journal of Epidemiology* 2002; 31:894-899
28. Hardie RM, Watson JM: Screening migrants at risk of tuberculosis. *BMJ* 1993; 307:1539-1540
29. Hawker JI, Bakhshi SS, Ali S, Farrington CP: Ecological analysis of ethnic differences in relation between tuberculosis and poverty. *BMJ* 1999; 319:1031-1034
30. Hayward AC, Darton T, Van-Tam JN, Watson JM, Coker R, Schwoebel V: Epidemiology and control of tuberculosis in Western European cities. *Int J Tuberc Lung Dis* 2003; 7:751-757
31. Heifets L: Are we on the brink of a new white plague in Russia? *Int J Tuberc Lung Dis* 2000; 4:1095-1096
32. Heifets L: WHO and Russia: the turning point in joint efforts against TB. *Int J Tuberc Lung Dis* 2003; 7:101-102

33. Ignatenko N, Srelis AK, Sharaburova OE, Mawer C, Lyagoshina TV, Golubchikova VT, Yanova GV, Eirikh IM, Healing TD, Sakseltseva NA, Besse C: Merlin and Tomsk Oblast Tuberculosis Services. Tomsk TB Project. The second meeting of the national tuberculosis programme managers from central and eastern Europe and the former USSR, 28-30 August 1996; WHO Bulletin No 3 Supplement 1997; 133-150
34. Iseman MD: Treatment of multidrug-resistant tuberculosis. *N Engl J Med* 1993; 329:784-791
35. Israel HL: Chemoprophylaxis for tuberculosis. *Respir Med* 1993; 87:81-83
36. Jefimova L: Bericht der Region Voronezh 1990-1995. Persönliche Mitteilung 1996
37. Jefimova L: Persönliche Mitteilung 1996
38. Kathri GR, Frieden TR: The status and prospects of tuberculosis control in India. *Int J Tuberc Lung Dis* 2000; 4:193-200
39. Khomenko AG, Punga VV, Grishina TA, Stain MB, Danilova ID, Rybka LN: WHO TB Control Project in the Ivanovo Oblast - Russian Federation. The second meeting of the national tuberculosis programme managers from central and eastern Europe and the former USSR, 28-30 August 1996; WHO Bulletin No 3 Supplement 1997; 71-84
40. Khomenko AG: The Ivanov Experience. *Tuberculosis & HIV* No 13; 12.96/1/2.97
41. Khomenko AG: Tuberculosis in Eastern Europe and the countries of the CIS. *Tuberculosis & HIV* No 13; 12.96/1/2.97
42. Kimerling ME, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, Portaels F, Matthys F: Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. *Int J Tuberc Lung Dis* 1999; 3:451-453
43. Kimerling ME: The Russian equation: an evolving paradigm in tuberculosis control. *Int J Tuberc Lung Dis* 2000; 4:S160-167
44. Kivihya-Ndugga LEA, van Cleeff MRA, Githui WA, Nganga LW, Kibuga DK, Odhiambo JA, Klatser PR: A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. *Int J Tuberc Lung Dis* 2003; 7:1163-1171
45. Konietzko N, Loddenkemper R (Hrsg): Tuberkulose. Georg Thieme Verlag Stuttgart New York 1999
46. Kononets AS (Justizministerium der Russischen Föderation): Persönliche Mitteilung. 30. Jahrestagung der Internationalen Union zur Bekämpfung der Tuberkulose und Lungenkrankheiten (IUATLD), Madrid 1999
47. Kretner B: Review of NPS activities in central and eastern Europe (CCEE) and the newly independent states (NIS). Persönliche Mitteilung. April 1997; 1-14

48. Lambregts-van Weezenbeek CSB, Veen J: Control of drug-resistant tuberculosis. *Tuberc Lung Dis* 1995; 76:455-459
49. Lapina AI: The development of tuberculosis control in the USSR. *Bull Int Union Tuberc* 1970; 43:188-195
50. Loddenkemper R, Hauer B, Sagebiel D, Forßbohm M: Tuberkuloseepidemiologie in Deutschland und der Welt mit Schwerpunkt Osteuropa. *Bundesgesundheitsbl – Gesundheitsforsch - Gesundheitsschutz* 1999; 42:683-693
51. Loddenkemper R: The need for antituberculosis drug resistance surveillance in Europe (Editorial). *Eur Respir J* 2000; 16:195-196
52. Loddenkemper R, Sagebiel D, Brendel A. Tuberculosis in the world, in Eastern Europe, and in Germany. *Phthisiopulmonology (Kasachstan)* 2002; 1:18-21
53. Loddenkemper R, Sagebiel D, Brendel A: Strategies against multidrug-resistant tuberculosis. *Eur Respir J* 2002; 20 (Suppl 36):66s-77s
54. Loddenkemper R, Sagebiel D: Control of tuberculosis in low prevalence countries. In Davies PDO (Hrsg): *Clinical Tuberculosis 3rd Ed* 2003; Arnold Publishers, London; 357-380
55. Loddenkemper R, Brendel A, Sagebiel D: Tuberkulose. Eine neue Bedrohung? *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2003; 46:52-58
56. Lygoshina TV: Russia. In Davies PDO (Hrsg): *Clinical Tuberculosis 2nd Ed* 1998; Chapman & Hall, London; 631-642
57. Menzies D: Tuberculosis crosses borders. *Int J Tuberc Lung Dis* 2000; 4:S153-S159
58. Menzies D: Screening immigrants to Canada for tuberculosis: Chest radiography or tuberculin skin testing? *CMAJ* 2003; 169:1035-1036
59. Migliori G, Raviglione M: Specific problems in developing areas of the world. Central and Eastern Europe. In Davies PDO (Hrsg): *Clinical Tuberculosis" 2nd Ed* 1998; Chapman & Hall, London; 643-660
60. Migliori GB, Raviglione MC, Schaberg T, Davies PDO, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L: Recommendations of a task force of the ERS, WHO and IUATLD (Europe region): TB management in Europe. *Eur Respir J* 1999; 14:978-992
61. Mitchison DA: How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. *Int J Tuberc Lung Dis* 1998; 2:10-15
62. Moulding TS, Redeker AG, Kanel GC: Twenty Isoniazid associated deaths in one state. *Am Rev Respir Dis* 1989; 140:700-705
63. Nitta AT, Knowles LS, Kim J, Lehnkering EL, Borenstein LA, Davidson PT, Harvey SM, de Koning ML: Limited transmission of multidrug-resistant tuberculosis

- despite a high proportion of infectious cases in Los Angeles County, California. *Am J Respir Crit Care Med* 2002; 165:812-817
64. O'Brian RJ, Nunn PP: The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. *Am J Respir Crit Care Med* 2001; 163:1055-1058
 65. Perelman MI: Tuberculosis in Russia. *Int J Tuberc Lung Dis* 2000; 4:1097-1103
 66. Pohle HD, Eljaschewitsch J: Persönliche Mitteilung. 1994
 67. Rabukhin AE: On some peculiarities of tuberculosis. Baku 1965. Quelle: Reichman LB, Hopkins Tanne J: Timebomb. The global epidemic of multi-drug-resistant tuberculosis. McGraw-Hill 2001
 68. Raviglione MC, Rieder HL, Styblo K, Khomenko AG, Esteves K, Kochi A: Tuberculosis trends in eastern Europe and the former USSR. *Tuberc Lung Dis* 1994; 75:400-416
 69. Raviglione MC, Snider DE, Kochi A: Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. *JAMA* 1995; 273:220-226
 70. Raviglione MC, Gupta R, Dye CM, Espinal MA: The burden of drug-resistant tuberculosis and mechanisms for its control. *Ann N Y Acad Sci* 2001; 953:88-97
 71. Reichman LB, Hopkins Tanne J: Timebomb. The global epidemic of multi-drug-resistant tuberculosis. McGraw-Hill 2001
 72. Reyes H, Coninx R: Pitfalls of tuberculosis programmes in prisons. *BMJ* 1997; 315:1447-1450
 73. Rieder HL, Cauthen GM, Comstock GW, Snider DE: Epidemiology of tuberculosis in the United States. *Epidemiol Rev* 1989; 11:79-98
 74. Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB: Tuberculosis control in Europe and international migration. *Eur Respir J* 1994; 7:1545-1553
 75. Rieder HL, Watson JM, Raviglione MC, Forssbohm M, Migliori GB, Schwoebel V, Leitch AG, Zellweger JP: Surveillance of TB in Europe. *Eur Respir J* 1996; 9:1097-1104
 76. Rieder HL: Interventions for tuberculosis control and elimination. IUATLD 2002: Paris, France; 1-251
 77. Robert Koch-Institut. HIV/AIDS-Bericht II/2000. *Epidemiologisches Bulletin*, Sonderausgabe 1/2001
 78. Robert Koch-Institut: Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2001. RKI 2003. 1-70
 79. Regierung der Russischen Föderation, Gesundheitsministerium: Prikaz (Edikt) No 527, 1988
 80. Regierung der Russischen Föderation, Gesundheitsministerium: Surveillance of tuberculosis. Methodological Guidelines. Chapter 3: Treatment and outpatient observation. Prikaz 324; Attachment No. 4; 22.11.1995

81. Regierung der Russischen Föderation, Gesundheitsministerium: Surveillance of tuberculosis. Methodological Guidelines. Chapter 3: Treatment and outpatient observation. Prikaz 324; Attachment No. 5; 22.11.1995
82. Regierung der Russischen Föderation: Federal Targeted Programme „Urgent measures for controlling tuberculosis in Russia during 1998-2004“. Resolution Nr. 582, 11.6.1998
83. Regierung der Russischen Föderation: Präsentation bei der Ministerkonferenz zu Tuberkulose und nachhaltiger Entwicklung, Amsterdam, Niederlande, 22. bis 24. März 2000
84. Regierung der Russischen Föderation, Gesundheitsministerium: Federal law on preventing tuberculosis dissemination in the Russian Federation. Federal law No. 77-F3, 18.6.2001. Rossyskaya Gazetta; 23.6.2001: 118:2730
85. Sagebiel D, Brendel A, Forßbohm M, Loddenkemper R: Gefährliche Zunahme multiresistenter Tuberkulosen in der ehemaligen Sowjetunion. Pneumologie 2002; 56:7-10
86. Sagebiel D, Hauer B, Loddenkemper R: Die Bedeutung der Tuberkulose – Aktuelle Trends und Entwicklungen. In Nienhaus A, Brandenburg S, Teschler H (Hrsg): Tuberkulose als Berufskrankheit – Ein Leitfadens zur Begutachtung 2003; ecomed – Medizin, Landsberg; 34-48
87. Sauerbruch F: Die historische Entwicklung der operativen Behandlung der Lungentuberkulose. Zeitschrift für Tuberkulose 1930; 57:289-294
88. Schaberg T, Gloger G, Reichert B, Mauch H, Lode H: Drug-resistant tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J 1995; 8:278-284
89. Schaberg T, Forßbohm M, Hauer B, Kirsten D, Kropp R, Loddenkemper R, Magdorf K, Rieder H, Sagebiel D, Urbanczik R (DZK): Richtlinien zur medikamentösen Behandlung der Tuberkulose im Erwachsenen- und Kindesalter. Pneumologie 2001; 55:494-511
90. Schilling W, Schnorr R, Landmann H: The tuberculosis situation in East European countries. Bull IUATLD 1989; 64:27-29
91. Shilova M: Vortrag auf dem 3. Kongress der International Union against Tuberculosis and Lung Disease (IUATLD), Europe Region in Moskau, Russische Föderation. Persönliche Mitteilung 6/2004
92. Small PM, Fujiwara PI: Management of tuberculosis in the United States. N Engl J Med 2001; 345:189-200
93. Snider DE, Tabas GJ: Isoniazid associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494-497
94. Tala-Heikkilä M, Tuominen JE, Tala EO: Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med 1998; 157:1324-1327
95. Talbot EA, Moore M, McCray E, Binkin NJ: Tuberculosis among foreign-born persons in the United States. JAMA 2000; 284:2894-2900

96. Tayler EM: Mantoux screening for tuberculosis. *The Lancet* 1995; 345:930-931
97. Tounghousova OS, Mariandyshev A, Bjune G, Sandven P, Caugant DA: Molecular epidemiology and drug resistance of *Mycobacterium tuberculosis* isolates in the Archangel Prison in Russia: predominance of the W-Beijing clone family. *CID* 2003; 37:665-672
98. Trnka L: BCG vaccination programmes in European countries 1995-2001. *Persönliche Mitteilung* 2002
99. UNAIDS: The changing HIV/AIDS Epidemic in Europe and Central Asia. *UNAIDS /04.18E*; 4/2004
100. Ursov IG: Prevention of tuberculosis. Novosibirsk 1991. Quelle: Reichman LB, Hopkins Tanne J. *Timebomb. The global epidemic of multi-drug-resistant tuberculosis*. McGraw-Hill 2001
101. Veen J: Microepidemics of tuberculosis: the stone-in-the-pond principle. *Tuberc Lung Dis* 1992; 73:73-76
102. Veen J, Raviglione MC, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R: Standardised outcome monitoring in Europe. Recommendations of a working group of the WHO and the IUATLD (Europe Region). *Eur Resp J* 1998; 12:505-510
103. Vosschulte K: Lunge. In Hellner H, Nissen R, Vosschulte K (Hrsg): *Lehrbuch der Chirurgie*. Georg Thieme Verlag Stuttgart 1964;490-493
104. Wares DF, Clowes CI: Tuberculosis in Russia. *Lancet* 1997; 350:957
105. White VLC, Moore-Gillon J: Resource implications of patients with multidrug resistant tuberculosis. *Thorax* 2000; 55:962-963
106. Wiesner B: Tuberkulose. In Konietzko N, Wendel H, Wiesner B (Hrsg): *Erkrankungen der Lunge*. Walter de Gruyter Verlag Berlin New York 1995; 546-574
107. The World Bank: *Investing in Health: World Development Report 1993*. New York, NY 1993; Oxford University Press
108. World Health Organization: *Managing Tuberculosis at District Level. A training course*. WHO Global TB Programme, Geneva 1996; WHO/TB/96.203
109. World Health Organization: *Managing Tuberculosis at National Level. A training course*. WHO Global TB Programme, Geneva 1992; WHO/TB/96.211
110. World Health Organization: *Tuberculosis, a global emergency: case notification update 2/1996*. Geneva; WHO/TB/96.197,
111. World Health Organization: *Treatment of tuberculosis. Guidelines for National programmes*. 2nd Ed 1997, Geneva; WHO/TB/97.220
112. World Health Organization: *Laboratory services in tuberculosis control Part I*. 1998, Geneva; WHO/TB/98.258
113. World Health Organization: *Laboratory services in tuberculosis control Part II*. 1998, Geneva; WHO/TB/98.258

114. World Health Organization: Laboratory services in tuberculosis control Part III. 1998, Geneva; WHO/TB/98.258
115. World Health Organization: Global tuberculosis control. WHO report 1999. Geneva 1999; WHO/TB/99.259
116. WHO/IUATLD: Antituberculosis drug resistance in the world. Report No. 2. Prevalence and trends. Geneva 2000; WHO/CDS/TB/2000.278
117. World Health Organization: Tuberculosis control in prisons. Geneva 2000; WHO/CDS/TB/2000.281
118. World Health Organization Europe: Strategy to control tuberculosis in the WHO European region. Copenhagen 2000; WHO/EUR/00/5017620
119. World Health Organization: Guidelines for establishing DOTS-Plus pilot projects. Geneva 2000, WHO/CDS/TB/2000.279
120. World Health Organization: Towards a TB-free future. Geneva 2002. WHO/CDS/STB/2001.13
121. World Health Organization: The global plan to stop TB. Geneva 2002. WHO/CDS/STB/2001.16
122. World Health Organization: Treatment of Tuberculosis. Guidelines for National Programmes. Geneva 2003; WHO/CDS/TB/2003.313
123. World Health Organization: Global TB Control. WHO Report 2003. Geneva 2003; WHO/CDS/TB/2003.316
124. World Health Organization Moskau: Recommendations with respect to the national guidelines on data recording and reporting for TB statistics using definitions harmonised between Russia and WHO, 2000. Persönliche Mitteilung Jakubowiak W, 2003
125. World Health Organization: Global Tuberculosis Control. WHO Report 2004. Geneva 2004; WHO/CDS/TB2004.331
126. WHO/IUATLD: Antituberculosis drug resistance in the world. Report No. 3. Prevalence and trends. Geneva 2004; WHO/CDS/TB/2004.xxx
127. Yerokhin VV, Punga VV, Rybka LN: Tuberculosis in Russia and the problem of multiple drug resistance. Ann NY Acad Sci 2001; 953:133–137
128. Zhukova MP, Punga VV, Kovaleva SI, Rybka LN, Nefedov BA, Nagornyi AM: Tuberculosis morbidity in the USSR population and its basic trends. Problemy Tuberculosa 1991; 11:22-24